F31 F32 F33 F25.1
Conditions
Interventions
Group 1: Inpatients (ICD F31, F32, F33, F25.1) who receive ECT treatment in addition to treatment with antidepressive drugs and psychotherapy. Depressive symptoms, blood values, biomedical imaging and
Sponsors
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: - Inpatients with a depressive episode (ICD-10 F31, F32, F33, F25.1; HAMD-21: =17) - Patients will only be included in the study after the study procedure has been explained in full and in detail and they have given their informed consent in writing
Exclusion criteria
Exclusion criteria: - Pregnant or breastfeeding women - Drug or alcohol addiction - Dementia - Depressive episode secondary to a somatic/neurological illness or substance dependence - Severe concomitant neurological or internal illness that may falsify the test results (e.g. recent myocardial infarction, Cushing's disease, underlying rheumatic diseases) - Other additional severe psychiatric comorbidities - The patient is unable to understand the nature and scope of the study and is therefore unable to give consent. - Inclusion not voluntary - Regular systemic intake of steroids or non-steroidal anti-inflammatory drugs (NSAIDs) - Incompatibility with MR measurement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of ECT and TAU with regard to their antidepressant efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigation of ECT-induced changes in molecular correlates of depression | — |
Countries
Germany
Contacts
Public ContactCaroline Nothdurfter
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg
Outcome results
None listed